Trial Profile
Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Ciraparantag (Primary)
- Indications Haemorrhage
- Focus Adverse reactions
- Sponsors Perosphere
- 29 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 05 Aug 2014 New trial record